Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UX-GIP001 in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy
NCT07572812Phase 1Recruiting
- Sponsor
- UniXell Biotechnology
- Start
- Sep 2026
- Primary completion
- Jul 2029
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of UX-GIP001 in mesial temporal lobe epilepsy (MTLE), sponsored by UniXell Biotechnology. Primary endpoint: Incidence and severity of Adverse Events (AEs)/Serious Adverse Events (SAEs) at 6 months. Started Sep 2026; status: recruiting.
02
Drugs
UX-GIP001
03
Conditions
mesial temporal lobe epilepsy (MTLE)
Beyond the preview
Go deeper on NCT07572812.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07572812.